1. Clinical & Scientific Overview
Telmisartan (TIP-MED-000002, Reference Code [3.2]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Agonist Activity.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.
Telma (Glenmark), Telmikind (Mankind), Tazloc (USV), Inditel (Zydus)
Oral Tablets: 20 mg, 40 mg, 80 mg
3. Mechanism of Action & Pharmacodynamics
Selectively and insurmountably blocks binding of Angiotensin II to the AT1 receptor in vascular smooth muscle and adrenal cortex (10,000-fold selectivity over AT2), inhibiting vasoconstriction and aldosterone secretion without inhibiting ACE/kininase II (no bradykinin cough); exhibits partial PPAR-γ agonism.
4. Therapeutic Indications & Evidence-Supported Uses
- Essential hypertension (first-line alone or with CCB/thiazide)
- Cardiovascular risk reduction in atherothrombotic disease
- Diabetic nephropathy with proteinuria in Type 2 DM
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults: 40 mg orally once daily; titrate to maximum 80 mg once daily. Full antihypertensive effect reached within 4–8 weeks.
Administration & Meal Timing: Oral; once daily with or without food. Remove hygroscopic blister tablet immediately before ingestion.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Contraindicated in severe hepatic impairment or biliary obstruction (since >97% cleared via bile). Max 40 mg/day in mild-to-moderate hepatic impairment.
No initial dose adjustment in mild-to-moderate renal impairment; monitor serum potassium and creatinine. Avoid in bilateral renal artery stenosis.
Contraindicated in severe hepatic impairment or biliary obstruction (since >97% cleared via bile). Max 40 mg/day in mild-to-moderate hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Pregnancy (2nd/3rd trimester — foetal renal dysplasia, oligohydramnios)
- Bilateral renal artery stenosis
- Biliary cholestasis or severe hepatic impairment
- Concomitant Aliskiren in diabetes or eGFR < 60 mL/min
Key Clinical Precautions: Contraindicated in severe hepatic impairment or biliary obstruction (since >97% cleared via bile). Max 40 mg/day in mild-to-moderate hepatic impairment.
8. Adverse Effects Profile
- Hyperkalaemia (especially in CKD or diabetic nephropathy)
- Symptomatic hypotension or orthostatic dizziness in volume-depleted patients
- Transient rise in serum creatinine (up to 20–30% haemodynamic dip)
- Rare angioedema (<0.1%, dramatically lower than ACE inhibitors)
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Potassium-sparing diuretics (Spironolactone), K+ supplements: additive hyperkalaemia
- NSAIDs (Diclofenac, Ibuprofen): blunts antihypertensive effect and precipitates Triple-Whammy AKI
- Lithium: Reversible elevation of serum lithium levels and toxicity
- Digoxin: Telmisartan increases peak plasma digoxin by 49%; monitor digoxin levels
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Keep tablets sealed in moisture-barrier aluminium-aluminium blisters until exact moment of taking (Telmisartan tablets are hygroscopic).
- Discontinue immediately and consult physician if pregnancy is detected.
- Avoid salt substitutes containing potassium chloride without checking serum K+.
Storage, Stability & Dispensing Safeguards: Store below 30°C in original moisture-proof Alu-Alu blister packaging.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.